JP Morgan raises Mirum Pharmaceuticals price target to $125
JP Morgan analyst Jessica Fye maintained an Overweight rating on Mirum Pharmaceuticals and raised the price target to $125 from $115, signaling confidence in the stock's future performance.

*this image is generated using AI for illustrative purposes only.
JP Morgan analyst Jessica Fye maintained an Overweight rating on Mirum Pharmaceuticals and raised the price target to $125 from $115. The adjustment reflects a positive outlook on the company's stock performance potential.
Rating and Price Target
The brokerage firm continues to endorse the stock with an Overweight rating, suggesting expectations for the shares to outperform the market average. The revised price target indicates an upside from the previous level of $115.
| Metric | Value |
|---|---|
| Rating | Overweight |
| New Price Target | $125 |
| Previous Price Target | $115 |
What specific factors drove the decision to raise the price target?
How might Mirum's upcoming product pipeline influence future stock performance?
What are the potential risks that could hinder the stock from reaching the new price target?




























